{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:41:02Z","timestamp":1790959262977,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Homologous recombination deficiency is a marker of response to poly(ADP-ribose) polymerase inhibitors in different cancer types including ovary, prostate, and pancreatic cancer. To date, no report about poly(ADP-ribose) polymerase inhibitors has been published on cervical cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>Here we present the case of a patient with cervical cancer treated in this setting. A 49-year-old woman diagnosed with International Federation of Obstetricians and Gynecologists stage 2018 IIIC2 locally advanced undifferentiated cervical cancer received first-line chemoradiotherapy followed by carboplatin, paclitaxel, and bevacizumab with partial response. Because of a family history of cancers, the patient was tested and found positive for a pathogenic <jats:italic>BRCA1<\/jats:italic> germline and somatic mutation, which motivated bevacizumab plus olaparib maintenance treatment. A simple hysterectomy was performed after 2\u00a0years stable disease; pathological report showed complete pathological response, and 12\u00a0months follow-up showed no recurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Poly(ADP-ribose) polymerase inhibitors could be an alternative maintenance treatment for patients with persistent advanced cervical cancer previously treated with platinum, especially when familial history of cancers is reported. Clinical trials using poly(ADP-ribose) polymerase inhibitors for advanced cervical cancer are warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-021-02767-9","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T23:10:31Z","timestamp":1619133031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Rosa","family":"Montero-Macias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4318-7894","authenticated-orcid":false,"given":"Meriem","family":"Koual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Crespel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Aude","family":"Le Fr\u00e9re-Belda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne Blons","family":"H\u00e9l\u00e8ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyen-Thu","family":"Nguyen-Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Garinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Balay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Durdux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Florin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"P\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Bats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"issue":"6","key":"2767_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"2767_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.critrevonc.2016.11.006","volume":"108","author":"S Boussios","year":"2016","unstructured":"Boussios S, Seraj E, Zarkavelis G, Petrakis D, Kollas A, Kafantari A, et\u00a0al. Management of patients with recurrent\/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. Crit Rev Oncol Hematol. 2016;108:164\u201374.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2767_CR3","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/S0020-7292(06)60030-1","volume":"95","author":"M Quinn","year":"2006","unstructured":"Quinn M, Benedet J, Odicino F, Maisonneuve P, Beller U, Creasman W, et\u00a0al. Carcinoma of the cervix uteri. Int J Gynecol Obstet. 2006;95:S43-103.","journal-title":"Int J Gynecol Obstet"},{"issue":"suppl_4","key":"2767_CR4","doi-asserted-by":"publisher","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","volume":"28","author":"C Marth","year":"2017","unstructured":"Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N, et\u00a0al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv72-83.","journal-title":"Ann Oncol"},{"issue":"8","key":"2767_CR5","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, et\u00a0al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734\u201343.","journal-title":"N Engl J Med"},{"issue":"3","key":"2767_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.clon.2016.10.002","volume":"29","author":"J McLachlan","year":"2017","unstructured":"McLachlan J, Boussios S, Okines A, Glaessgen D, Bodlar S, Kalaitzaki R, et\u00a0al. The impact of systemic therapy beyond first-line treatment for advanced cervical cancer. Clin Oncol (R Coll Radiol). 2017;29(3):153\u201360.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2767_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/ijgo.12620","volume":"143","author":"P Basu","year":"2018","unstructured":"Basu P, Mukhopadhyay A, Konishi I. Targeted therapy for gynecologic cancers: toward the era of precision medicine. Int J Gynecol Obstet. 2018;143:131\u20136.","journal-title":"Int J Gynecol Obstet"},{"issue":"3","key":"2767_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11864-015-0378-9","volume":"17","author":"FW Liu","year":"2016","unstructured":"Liu FW, Tewari KS. New targeted agents in gynecologic cancers: synthetic lethality, homologous recombination deficiency, and PARP inhibitors. Curr Treat Options Oncol. 2016;17(3):12.","journal-title":"Curr Treat Options Oncol"},{"issue":"27","key":"2767_CR9","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1200\/JCO.19.00347","volume":"37","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Mirza M, Coleman R. The DNA repair pathway as a target for novel drugs in gynecologic cancers. J Clin Oncol. 2019;37(27):2449\u201359.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2767_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s11523-019-00680-2","volume":"14","author":"E Sachdev","year":"2019","unstructured":"Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM. PARP inhibition in cancer: an update on clinical development. Targ Oncol. 2019;14(6):657\u201379.","journal-title":"Targ Oncol"},{"key":"2767_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ygyno.2015.01.351","volume":"137","author":"R Feldman","year":"2015","unstructured":"Feldman R, Gatalica Z, Reddy SK, Tewari KS. Paving the road to personalized medicine in cervical cancer: theranostic biomarker evaluation in a 592-specimen library. Gynecol Oncol. 2015;137:141.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2767_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40268-020-00301-8","volume":"20","author":"S Boussios","year":"2020","unstructured":"Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, et\u00a0al. Poly (ADP-ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond. Drugs R D. 2020;20(2):55\u201373.","journal-title":"Drugs R D"},{"issue":"3","key":"2767_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0304-3835(81)90148-8","volume":"14","author":"M Fukushima","year":"1981","unstructured":"Fukushima M, Kuzuya K, Ota K, Ikai K. Poly(ADP-ribose) synthesis in human cervical cancer cell\u2014diagnostic cytological usefulness. Cancer Lett. 1981;14(3):227\u201336.","journal-title":"Cancer Lett"},{"issue":"3","key":"2767_CR14","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/IGC.0000000000000380","volume":"25","author":"C Kunos","year":"2015","unstructured":"Kunos C, Deng W, Dawson D, Lea JS, Zanotti KM, Gray HJ, et\u00a0al. A phase I-II evaluation of Veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology\/Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2015;25(3):484\u201392.","journal-title":"Int J Gynecol Cancer"},{"issue":"1\u20132","key":"2767_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11010-008-9894-2","volume":"320","author":"U Ghosh","year":"2009","unstructured":"Ghosh U, Bhattacharyya NP. Induction of apoptosis by the inhibitors of poly(ADP-ribose)polymerase in HeLa cells. Mol Cell Biochem. 2009;320(1\u20132):15\u201323.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"2767_CR16","doi-asserted-by":"publisher","first-page":"12876","DOI":"10.1038\/s41598-017-13232-3","volume":"7","author":"CB Prasad","year":"2017","unstructured":"Prasad CB, Prasad SB, Yadav SS, Pandey LK, Singh S, Pradhan S, et\u00a0al. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci Rep. 2017;7(1):12876.","journal-title":"Sci Rep"},{"issue":"1","key":"2767_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ygyno.2019.08.010","volume":"155","author":"A Bianchi","year":"2019","unstructured":"Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, et\u00a0al. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecol Oncol. 2019;155(1):144\u201350.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2767_CR18","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ajpath.2010.12.004","volume":"178","author":"X Ba","year":"2011","unstructured":"Ba X, Garg NJ. Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. Am J Pathol. 2011;178(3):946\u201355.","journal-title":"Am J Pathol"},{"issue":"5","key":"2767_CR19","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1073\/pnas.0904783107","volume":"107","author":"DC Hegan","year":"2010","unstructured":"Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci. 2010;107(5):2201\u20136.","journal-title":"Proc Natl Acad Sci"},{"issue":"29","key":"2767_CR20","doi-asserted-by":"publisher","first-page":"26995","DOI":"10.18632\/oncotarget.4863","volume":"6","author":"AN Weaver","year":"2015","unstructured":"Weaver AN, Cooper TS, Rodriguez M, Trummell HQ, Bonner JA, Rosenthal EL, et\u00a0al. DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma. Oncotarget. 2015;6(29):26995\u20137007.","journal-title":"Oncotarget"},{"issue":"4","key":"2767_CR21","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s12253-012-9523-y","volume":"18","author":"MK Hassumi-Fukasawa","year":"2012","unstructured":"Hassumi-Fukasawa MK, Miranda-Camargo FA, Zanetti BR, Galano DF, Ribeiro-Silva A, Soares EG. Expression of BAG-1 and PARP-1 in precursor lesions and invasive cervical cancer associated with human papillomavirus (HPV). Pathol Oncol Res. 2012;18(4):929\u201337.","journal-title":"Pathol Oncol Res"},{"issue":"3","key":"2767_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/annonc\/mdw635","volume":"28","author":"PH Thaker","year":"2017","unstructured":"Thaker PH, Salani R, Brady WE, Lankes HA, Cohn DE, Mutch DG, et\u00a0al. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Ann Oncol. 2017;28(3):505\u201311.","journal-title":"Ann Oncol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02767-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-02767-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-02767-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T23:37:29Z","timestamp":1619134649000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-02767-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2767"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-02767-9","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"assertion":[{"value":"2 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}